Ngomhlaka-10 Mashi 2026, i-B7-H3-targeting antibody-drug conjugate (ADC) YL201 entsha yokujova, eyasungulwa yiMediLink Therapeutics, yanikezwa i-Breakthrough Therapy Designation yi-Center for Drug Evaluation of China's National Medical Products Administration. Isibonakaliso esibekiwe sihlanganiswe ne-Serplulimab yokwelapha umdlavuza wamaphaphu wesigaba esikhulu (ES-SCLC).
I-YL201 iyi-ADC entsha ehlose ngqo i-B7H3. Iphrotheni ye-B7H3 ikhiqizwa kakhulu kumaseli anobungozi kanye namaseli aqala umdlavuza ezinhlobo ezahlukene zamathumba kodwa inokubonakaliswa okulinganiselwe ezicutshini ezivamile, okugqamisa amandla ayo njengomuthi we-ADC. I-YL201 yathuthukiswa kusetshenziswa ubuchwepheshe be-MediLink's Tumor Microenvironment Activable LINKer-payload (TMALIN®) obuhlanganiswe ne-antibody ye-B7H3 ekhethekile kakhulu. Njengamanje, i-YL201 iyaphenywa ezinhlotsheni ezahlukahlukene zamathumba aqinile futhi ingenele izivivinyo zesigaba esibalulekile ku-Small Cell Lung Cancer kanye ne-Nasopharyngeal Carcinoma eShayina.
### Imininingwane Yezokwelapha Egunyaziwe: Ukusebenza Okuphawulekayo Nokuphepha Okuhle
NgoMashi 2025, iphephabhuku lomhlaba wonke elihamba phambili *Nature Medicine* lashicilela idatha evela esivivinyweni somtholampilo seSigaba 1/1b se-YL201 ezigulini ezinezimila eziqinile ezithuthukile. Lolu cwaningo, oluhlanganisa iziguli ezingu-312, lubonise:
- **Ukusebenza Kokuphelele:** Phakathi kweziguli ezingu-287 ezihlolwayo, izinga lokuphendula eliqondile (ORR) laliyi-40.8% ehlaba umxhwele, kufaka phakathi iziguli ezimbili ezithola impendulo ephelele (CR) kanye nezingu-115 ezithola impendulo engaphelele (PR). Izinga lokulawula izifo (DCR) lifinyelele ku-83.6%.
- **Umdlavuza Wamaphaphu Weseli Elincane Elisezingeni Elibanzi (ES-SCLC):** Ezigulini ezelashwe ngaphambilini nge-chemotherapy esekelwe eplatinum, i-ORR yayingu-63.9%, i-DCR yayingu-91.7%, kanti ukusinda okungenawo ama-progression-free (mPFS) okumaphakathi kwakuyizinyanga ezingu-6.3.
- **I-Nasopharyngeal Carcinoma (NPC):** Phakathi kweziguli ezingu-70, i-ORR yayingu-48.6%, i-DCR yayingu-92.9%, kanti iziguli ezimbili zathola impendulo ephelele. Isikhathi esimaphakathi sempendulo (mDOR) sasifinyelela ezinyangeni ezingu-8.4.
Le mininingwane iqinisekisa ngokugcwele umsebenzi onamandla wokulwa nomdlavuza kanye nephrofayili yokuphepha elawulekayo ye-YL201 ezinhlotsheni eziningi zezimila eziqinile ezithuthukile, ibeka isisekelo esiqinile socwaningo lwezokwelapha olulandelayo kanye nokusetshenziswa okubanzi.
### UMnyango Wezangaphandle Wesibhedlela Se-Oncology Sesifunda SaseNingizimu saseBeijing: Ibhuloho Lakho Lokuya Kwezokwelapha Zamazwe Ngamazwe
UMnyango Wezizwe Ngezizwe Wesibhedlela i-Beijing South Region Oncology Hospital uzinikele njalo ekwethuleni ubuchwepheshe kanye nemithi ehamba phambili emhlabeni jikelele yokuxilonga nokwelapha umdlavuza. Silandela eduze inqubekela phambili yocwaningo olusezingeni eliphezulu futhi sigcina ukubambisana okuqinile nezikhungo zesayensi eziphezulu ngaphakathi nangaphandle, silwela ukunikeza iziguli zomhlaba wonke ukufinyelela ngesikhathi esifanele ezinkethweni zokwelapha eziphumelelayo okuhlanganisa i-YL201.
Ithimba lethu lezinsizakalo zeziguli zomhlaba wonke lingakunikeza lokhu:
- **Ukuhlolwa Kwezokwelapha Okuqondene Nakho:** Ithimba lezifundo eziningi (i-MDT) lizohlola ngokuphelele amarekhodi akho ezokwelapha ukuze linqume ukuthi ukwelashwa kwe-ADC kuyafaneleka yini esimweni sakho.
- **Ukufinyelela Okunakekelwayo Okulula:** Usizo lokuthola ama-visa okuya eShayina, ukuhlela ukubonisana nochwepheshe, ukuhlela izinsizakalo zokuhumusha, kanye nokuxhumanisa ukwamukelwa esibhedlela ukuze uthole ulwazi olungenakukhathazeka.
### Xhumana Nathi Manje Ukuze Uthole Ulwazi Olwengeziwe
Uma wena noma othandekayo wakho nibhekene nezinselele ezihlobene nomdlavuza wamaphaphu wamangqamuzana amancane, i-nasopharyngeal carcinoma, noma ezinye izimila eziqinile ezithuthukile, futhi nifisa ukufunda imininingwane eyengeziwe mayelana nokwelashwa kwe-ADC okuphambili noma ukuhlola amathuba okwelashwa, sicela uxhumane noMnyango Wezangaphandle Wesibhedlela iBeijing South Region Oncology Hospital ngokushesha. Ochwepheshe bethu Bezinsizakalo Zeziguli Zamazwe Ngamazwe bazophendula umbuzo wakho zingakapheli amahora angama-24.
**Ulwazi lokuxhumana:**
- **Ucingo:** 400-880-3716���
- **WeChat:** 17801183037
- **I-imeyili:**
100085_010@163.com
myimmnet@163.com
Siyaqonda ukuthi indlela yokwelashwa komdlavuza inzima, kodwa yonke impumelelo isho ithemba elisha. UMnyango Wezangaphandle Wesibhedlela i-Beijing South Region Oncology Hospital International ufisa ukuma nani, nisebenzisa ubuchwepheshe bezokwelapha obungochwepheshe kanye nokunakekelwa okufudumele nokunesihawu, ukuze ninqobe umdlavuza ngokubambisana futhi namukele ukuqala kwempilo.
Isikhathi sokuthunyelwe: Mashi-24-2026